Introduction: Lung adenocarcinoma (ADC) with synchronous ground-glass/lepidic (GG/L) nodules is considered a distinct disease entity in multiple synchronous lung cancers. Few studies have performed next-generation sequencing analysis of these synchronous sequential lesions, and genetic alterations of GG/L nodules must be further investigated.
Introduction
Multiple synchronous lung cancers (MSLCs) account for 0.2% to 20% of lung cancers, and the prevalence of MSLCs has been increasing because of advances in imaging technology. It is critical to distinguish whether they are independent tumors or intrapulmonary metastasis, because this distinction results in different prognoses and treatment strategies. As a category of MSLC, lung adenocarcinoma (ADC) commonly accompanies synchronous ground-glass/lepidic (GG/L) nodule(s), which are pathologically correlated to atypical adenomatous hyperplasia (AAH), ADC in situ (AIS), minimally invasive ADC (MIA), or lepidicpredominant ADC. Multiple GG/L nodules are considered a distinct disease entity in the eighth edition of TNM classification because they are predominantly detected in women and never-smokers and show better prognosis than other MSLCs. 1 In addition, GG/L nodules are known to follow a stepwise progression from AAH, to AIS, to MIA, and to ADC because of their histologic continuum. 2 Although recent studies have performed NGS analyses to delineate sequential genetic alteration toward ADC, 3, 4 genetic alterations of early glandular lesions need to be further investigated. In this study, we performed targeted deep sequencing in ADC and synchronous AAH, AIS, and MIA. We attempted to delineate genetic alterations in synchronous sequential lesions and clarify their genetic relationship. HiSeq 2500 sequencer (Illumina, San Diego, CA). The average read depth was Â539. Variant discovery and genotype calling of single-nucleotide variants (SNVs) were conducted with Genomon pipeline software (https://github.com/Genomon/genomon) with default parameters. The candidate variants located in exonic regions were annotated by using ANNOVAR software. R software was used for statistical analyses, and the ggplot2 and VennDiagram packages were used for data visualization.
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Mutational Profiles of Multiple Synchronous Lesions
In the multiple synchronous lesions of each patient, mutation profiles were not identical. Instead, a few shared mutations, including EGFR and KRAS mutations, were observed in synchronous lesions ( Supplementary Fig. 1 ). The variant allele frequency (VAF) of EGFR and KRAS increased with the progression of lesions (Table 2) . In 10 patients, all or some of the synchronous lesions had mutations in the same genes ( Supplementary Fig. 2 ). Among them, EGFR was the most frequently shared mutated gene. EGFR mutation was identified in 36.5% of all samples (19 of 52) and 75% of ADCs (12 of 16). Of 12 patients harboring EGFR-mutant ADC, five had EGFR mutations in their synchronous GG/L nodules (Table 3) . In patients with EGFR wild-type ADC, EGFR mutation was not identified in their synchronous GG/L nodules. All EGFR mutations involved the kinase domain, and mutant loci were identical or different in synchronous lesions. 
Comparison of the Lepidic and Invasive Portions of ADCs
In 10 ADC samples with well-defined lepidic and invasive portions, an average of 6.0 mutations per lepidic portion of ADC (range 2-21) and an average of 5.4 mutations per invasive ADC (range 4-16) were identified. An average of 37.3% of mutations (range 11%-67%) were overlapped between the lepidic portion of ADC and corresponding invasive ADC. In 9 out of 10 ADC samples, EGFR, KRAS, and BRAF mutations showed homogenous distribution in the lepidic and invasive portions ( Table 4 ).
Discussion
This study showed different mutation profiles among the synchronous lesions, indicating that these lesions can be considered genetically independent tumors. However, EGFR and KRAS mutations were shared in some synchronous lesions. The EGFR and KRAS mutations showed an increase in VAF in the sequence of AAH, to MIA, and to ADC. Previous studies of ADC and synchronous early lesions compared EGFR and KRAS mutation status and reported that a small subset of synchronous lesions could be clonal. [5] [6] [7] In a comparison of lung ADC and adjacent nonneoplastic lung epithelium, identical EGFR and KRAS mutations were observed in the never-smoker and heavy smoker groups, respectively. 8, 9 The authors suggested that these identical genetic alterations might occur even before tumorigenesis and that these mutations might be the initial events causing multiple occurrences of tumors. Moreover, the increase in VAF in advanced lesions suggests their spatial expansion along the epithelium. 3 In this study, synchronous lesions of 10 patients shared mutated genes, and mutations of EGFR were the most frequently shared. In a sequencing analysis by Liu et al., 10 EGFR or KRAS mutations with identical or different mutant loci were shared in synchronous ADCs. With this finding, the authors suggested that MSLCs have possible selection constraints around certain genes or pathways that are critical for carcinogenesis in specific patients. Ma et al. 11 determined that different driver mutations in synchronous cancers were functionally interchangeable, and they proposed that MSLCs are constrained by selection for functional convergence of tumorigenic pathways.
Although each individual lesion showed a diverse range of mutations, some characteristic mutation patterns were observed in each lesion type. AAH showed high rates of KRAS, BRAF, and EGFR mutation; ADC showed the highest rate of EGFR mutation among the four types of lesions, with relatively low rates of KRAS and BRAF mutation. Previous studies showed similar or increased rates of EGFR mutation in AAH, AIS, and ADC and suggested a role of EGFR mutations in both early tumorigenesis and malignant progression. 7, 12, 13 In recent studies, BRAF, KRAS, and EGFR showed higher mutation rates in AAH, and only EGFR mutations were more frequently identified in MIA or ADC.
3,4 EGFR-mutant GG/L nodules were also found to be significantly associated with the growth of GG/L nodules.
14 These findings suggest that BRAF, KRAS, and EGFR mutations are involved in AAH initiation and that EGFR-mutant AAH may be more likely to progress to ADC than are KRAS-or BRAF-mutant AAH. In addition, we observed frequently mutated genes other than driver genes; they included LRP1B in AAH, MAP2K1 in AIS, and RBM10 in MIA. These gene mutations have been reported in lung ADC, and they are regarded to contribute to ADC pathogenesis. In our data, they were identified in early lesions, which supports the relevance of these genes in early carcinogenesis of lung ADC.
The mutation rate did not increase from AAH to progressed lesions; rather, it increased according to smoking history (Supplementary Fig. 3 ). On the other hand, ADC showed a distinctly high VAF in driver gene mutations. Generally, stepwise tumor progression is known to be accompanied by accumulation of genetic alterations. However, our results would indicate that the presence of driver gene mutations with a high VAF is more important than quantitative mutational accumulation. This finding will be confirmed by comparison analysis with whole-exome sequencing or transcriptome sequencing in our ongoing studies.
When mutations of the lepidic and invasive parts of ADC were compared, intratumoral heterogeneity was identified but mutations of well-known driver genes-EGFR, KRAS, and BRAF mutations-were homogenously distributed. These results are in agreement with those of previous studies demonstrating that driver gene mutations are involved in early-stage tumorigenesis before clonal expansion. 15 In conclusion, this study suggested that ADC and synchronous GG/L nodules are genetically independent tumors. Intratumoral genetic heterogeneity of ADC was present, but driver gene mutations were homogeneously distributed. In addition, driver gene mutations with a high VAF were identified in the invasive tumor.
